Supported content
Independently created content that is financially supported by our commercial partners. The Pharmaceutical Journal retains editorial responsibility.

BTK inhibitors: what pharmacists need to know

In this episode of The PJ Pod, we consider the impact bruton tyrosine kinase (BTK) inhibitors have had on care for patients with B-cell malignancies and explore how pharmacists can help patients get the best out of their treatment regimens.

Bruton tyrosine kinase (BTK) inhibitors are used to treat cancers caused by defective B cells, such as chronic lymphocytic leukaemia, B-cell lymphomas and Waldenström macroglobulinemia (WM). While B-cell malignancies are relatively rare cancers, their incidence is increasing. There are significant side effects and drug interactions associated with these therapies, and as the clinical use of BTK inhibitors increases, so does the need for pharmacists and pharmacy teams to be aware of them.

In this episode of The PJ Pod, Caitlin Killen, assistant clinical editor, speaks to a patient who has received these therapies, as well as with two experts to find out more about the different BTK inhibitor classes, their mechanisms of action and considerations for their use in practice, with a focus on WM.

Many thanks to expert patient Harriet Scorer; Shirley D’Sa, consultant haematologist and clinical lead for the University College London Hospitals Centre for WM; and Jaimal Kothari, a consultant haematologist based in Oxford, for their expertise.

This episode was produced by Geoff Marsh.

Want to hear more from The PJ Pod? Follow us on Spotify, Google Podcasts, Apple Podcasts or other popular podcast platforms to listen to our latest episodes.

Disclosures and conflicts of interest

Harriet Scorer is a trustee of WM UK.

Shirley D’Sa is on advisory boards for Janssen, BeiGene and Sanofi. She has received speaker’s fees from BeiGene and Janssen, and research funding from BeiGene.

Jaimal Kothari is on the advisory board for BeiGene. He has received honoraria from BeiGene, Takeda and Janssen, and research funding from MSD.

Last updated
The Pharmaceutical Journal, PJ, October 2023, Vol 311, No 7978;311(7978)::DOI:10.1211/PJ.2023.1.197887

    Please leave a comment 

    You may also be interested in